InvestorsHub Logo
Followers 33
Posts 2837
Boards Moderated 2
Alias Born 10/24/2015

Re: jondoeuk post# 13

Thursday, 12/17/2020 2:50:10 PM

Thursday, December 17, 2020 2:50:10 PM

Post# of 151
Today, they announced three new exclusive license agreements.

A humanised scFv targeting CLEC12A licensed from Cellerant Therapeutics, creates a fourth preclinical program, ONKT104, for the treatment of acute myeloid leukaemia.

A humanised scFv targeting MUC1 licensed from Glycotope GmbH.

A CCR7 homing receptor licensed from the US NIH, for use in ONKT101, for R/R B-cell malignancies.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NKTX News